Respironics to Market New Nebulizer System

A new nebulizer system that offers improved pulmonary drug delivery efficiency and has the potential to reduce drug and personnel costs in the critical care setting will be marketed worldwide by Respironics, Inc. (Murrysville, PA, USA) under a nonexclusive agreement with Aerogen, Inc. (Mountain View, CA, USA).

Respironics will market and distribute the nebulizer with its new and existing ventilator support systems. The nebulizer, called Aeroneb Pro, incorporates Aerogen's proprietary OnQ aerosol generator, designed to improve the delivery of drugs for respiratory disorders in a critical care setting. Respironics is a leading developer, manufacturer, and distributor of products and programs that serve global sleep and respiratory markets.

"We're pleased to be working with Respironics, a worldwide leader in the development and commercialization of respiratory products,” noted Dr. Jane Shaw, chairman and CEO of Aerogen. "This relationship will expand the market penetration of our Aeroneb Pro for aerosolized delivery of respiratory therapies in the critical care setting.”

Aerogen develops drug-device combination aerosol products based on its OnQ generator technology to improve treatment of respiratory disorders. The company has reported the results of a phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia. Additional drugs targeting improved respiratory therapy are in the feasibility and preclinical stages of development.





Related Links:
Respironics
Aerogen